Immodulon Therapeutics is a British biotechnology company based in Uxbridge, England.
COVID-19
Immodulon participated in the COV-IMMUNO clinical trial to evaluate IMM-101 for its use as a COVID-19 vaccine.[1]
Organization
Immodulon is an industry partner of BioCanRx.[2]
External links
Canadian Cancer Trials Group. (2023, January 31). Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure. ClinicalTrials.gov. https://web.archive.org/web/20230710183029mp_/https://classic.clinicaltrials.gov/ct2/show/NCT04442048 ↩︎
Our Partners & Collaborators. BioCanRx. Retrieved September 27, 2022, from http://archive.today/2022.09.28-044532/https://biocanrx.com/partnerships/our-partners%23 ↩︎
